Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Enough Is enough

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Jan 12, 2024 12:48pm

66 Views

Post# 35823888

RE:RE:RE:RE:Enough Is enough

Yes Year3000 this is beginning to look grim. It they have nothing to update then we can conclude all aspects of this company are "dead in the water". This is very disturbing. Those holding shares are not willing to sell at $.06 which is next to "worthless" for many of us. On the other hand it looks like there is 1 buyer buying 10,000 shares at $.06.....Wow.

<< Previous

Bullboard Posts

Next >>

Critical raw materials pioneer drives Europe’s clean energy transition